Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects

Pneumococcal infection is a major cause of pneumonia, bacteremia, and meningitis. Incidence of pneumococcal disease (PD) varies worldwide. The 23-valent pneumococcal polysaccharide vaccine (PPV23) displays an acceptable safety profile and has been demonstrated cost-effective in reducing burden of PD...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Hum Vaccin Immunother
Päätekijät: Ciprero, Karen, Zykov, Kirill A., Briko, Nikolay I., Shekar, Tulin, Sterling, Tina M., Bitieva, Elizaveta, Stek, Jon E., Musey, Luwy
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2016
Aiheet:
Research Papers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4994758/
https://ncbi.nlm.nih.gov/pubmed/27149114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1165373
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia